Core Viewpoint - TransMedics Group (TMDX) is experiencing strong demand for its organ transplant technology and services, leading to significant stock gains and positioning the company for potential investment opportunities in 2026 [1] Financial Performance - TransMedics reported a fourth-quarter profit of $2.62 per share, a surge of over 1000% from 19 cents per share a year ago, exceeding analysts' expectations of 36 cents per share [1] - Fourth-quarter sales increased by 32% to $161 million, although this was below the analysts' target of $174 million [1] - Earnings have more than doubled in the last three quarters, contributing to the company's profitability over the past two years [1] Market Position - The stock has formed a cup-with-handle base with a buy point of 151.85, indicating a potential breakout opportunity [1] - TransMedics ranks fourth in the medical products group, with a Composite Rating of 96 out of 99 and a Relative Strength Rating of 89, indicating strong performance compared to other stocks [1] - The stock has gained 21% year to date, and mutual funds have been net buyers over the past 13 weeks, resulting in an Accumulation/Distribution Rating of B+ [1] Future Outlook - Analysts predict a 47% decline in earnings growth for 2026, estimating profit to drop to $2.56 per share, but expect a rebound in 2027 with a 45% increase to $3.71 per share [1] - For 2026, TransMedics has provided revenue guidance of $742 million, closely aligning with the FactSet consensus estimate of $737.5 million [1]